Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHB4 | P54760 | 15/20 | 0.64 |
| ▸ | KDR | P35968 | 2/20 | 0.55 |
| ▸ | TEK | Q02763 | 2/20 | 0.55 |
| ▸ | AURKA | O14965 | 5/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6222008 | 0.91 | EPHB4 (0.53) | EPHB4KDRTEKAURKA | |
| SCHEMBL6223356 | 0.83 | EPHB4 (0.70) | EPHB4KDRTEKAURKA | |
| SCHEMBL5478193 | 0.83 | EPHB4 (0.67) | EPHB4KDRTEKAURKA | |
| SCHEMBL7041330 | 0.82 | AURKA (0.59) | EPHB4KDRTEKAURKA | |
| SCHEMBL5480343 | 0.82 | EPHB4 (0.62) | EPHB4KDRTEKAURKA | |
| SCHEMBL6222910 | 0.81 | EPHB4 (0.47) | EPHB4KDRTEKAURKA | |
| SCHEMBL6221467 | 0.81 | EPHB4 (0.52) | EPHB4KDRTEKAURKA | |
| SCHEMBL5482588 | 0.80 | EPHB4 (0.70) | EPHB4KDRTEKAURKA | |
| SCHEMBL4346366 | 0.78 | SYK (0.57) | EPHB4KDRTEK | |
| SCHEMBL5478356 | 0.77 | EPHB4 (0.59) | EPHB4KDRTEKAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7312341-B2 | 6-aryl-imidazo[1,2-a] pyrazin-8-ylamines, method of making, and method of use thereof | CGI PHARMACEUTICALS, INC. (US) | 2007-12-25 | — | — | US | claimed |
| US-6919340-B2 | Imidazo[1,2-a]pyrazin-8-ylamines, method of making, and method of use thereof | CELLULAR GENOMICS, INC. (US) | 2005-07-19 | — | — | US | claimed |
| EP-1509526-A2 | IMIDAZO(1,2-A)PYRAZIN-8-YLAMINES, METHOD OF MAKING, AND METHOD OF USE THEREOF | Cellular Genomics Inc. (US) | 2005-03-02 | — | — | EP | claimed |
| US-20040067951-A1 | 6-aryl-imidazo[1,2-a] pyrazin-8-ylamines, method of making, and method of use thereof | GILEAD CONNECTICUT, INC. | 2004-04-08 | — | — | US | claimed |
| US-20030212073-A1 | Imidazo[1,2-a]pyrazin-8-ylamines, method of making, and method of use thereof | GILEAD CONNECTICUT, INC. | 2003-11-13 | — | — | US | claimed |
| WO-2003089434-A2 | IMIDAZO[1,2-a]PYRAZIN-8-YLAMINES METHOD OF MAKING AND METHOD OF USE THEREOF | CELLULAR GENOMICS, INC. (US) | 2003-10-30 | — | — | WO | claimed |
| US-7312341-B2 | 6-aryl-imidazo[1,2-a] pyrazin-8-ylamines, method of making, and method of use thereof | CGI PHARMACEUTICALS, INC. (US) | 2007-12-25 | — | — | US | disclosed |
| US-20050288295-A1 | Certain imidazo[1,2-a]pyrazin-8-ylamines, method of making, and method of use thereof | CGI PHARMACEUTICALS, INC. | 2005-12-29 | — | — | US | disclosed |
| US-6919340-B2 | Imidazo[1,2-a]pyrazin-8-ylamines, method of making, and method of use thereof | CELLULAR GENOMICS, INC. (US) | 2005-07-19 | — | — | US | disclosed |
| WO-2005047290-A2 | IMIDAZO[1,2-A] PYRAZIN-8-YLAMINES AS KINASE INHIBITORS | CELLULAR GENOMICS INC. (US) | 2005-05-26 | — | — | WO | disclosed |
| EP-1509526-A2 | IMIDAZO(1,2-A)PYRAZIN-8-YLAMINES, METHOD OF MAKING, AND METHOD OF USE THEREOF | Cellular Genomics Inc. (US) | 2005-03-02 | — | — | EP | disclosed |
| US-20040067951-A1 | 6-aryl-imidazo[1,2-a] pyrazin-8-ylamines, method of making, and method of use thereof | GILEAD CONNECTICUT, INC. | 2004-04-08 | — | — | US | disclosed |
| WO-2004022562-A1 | 6-ARYL-IMIDAZO[1,2-a]PYRAZIN-8-YLAMINES, METHOD OF MAKING, AND METHOD OF USE THEREOF | CELLULAR GENOMICS, INC. (US) | 2004-03-18 | — | — | WO | disclosed |
| WO-2003089434-A2 | IMIDAZO[1,2-a]PYRAZIN-8-YLAMINES METHOD OF MAKING AND METHOD OF USE THEREOF | CELLULAR GENOMICS, INC. (US) | 2003-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040067951-A1 | 6-aryl-imidazo[1,2-a] pyrazin-8-ylamines, method of making, and method of use thereof | MAP3K8, PRKACA, MAP3K1 | EPHB4 4062/4885KDR 1716/4885TEK 1568/4885 |
| US-20030212073-A1 | Imidazo[1,2-a]pyrazin-8-ylamines, method of making, and method of use thereof | PRKACA, MAP3K8, MAP3K1 | EPHB4 4069/4885KDR 2244/4885TEK 2063/4885 |
| US-20050288295-A1 | Certain imidazo[1,2-a]pyrazin-8-ylamines, method of making, and method of use thereof | MAP3K8, MAP3K1, PRKACA | EPHB4 4328/4885KDR 1580/4885TEK 2114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.